Home › Myelodysplastic Syndromes › New York
Myelodysplastic Syndromes clinical trials in New York
38 studies for Myelodysplastic Syndromes are looking for participants at sites in New York.
Cities in New York
- New York City21 studies
- The Bronx9 studies
- Buffalo8 studies
- Rochester6 studies
- Queens6 studies
- Greenburgh5 studies
- New Rochelle3 studies
- Staten Island3 studies
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Stony Brook University Medical Center, Stony Brook
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06484062A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Northwell Health/Center for Advanced Medicine, Lake Success
- and 9 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Montefiore, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Hematology Oncology Associates of Rockland, Nyack
- Albert Einstein College - Montefiore, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07422480Collection of Tissue Samples for Cancer Research
- Roswell Park Cancer Institute, Buffalo
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198A Telehealth Advance Care Planning Intervention
- University of Rochester, Rochester
Recruiting
Ages 60 and older · All sexes · Updated Sep 11, 2026 · NCT05875805Cord Blood Transplant in Adults With Blood Cancers
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 21 to 65 · All sexes · Updated Sep 11, 2026 · NCT05884333Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- MSKCC, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- NYU Langone Hospital - Long Island, Mineola
- and 7 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Northwell Health, Lake Success
- Clinical Research Alliance NY, Westbury
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06499285A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- New York Cancer and Blood, Shirley
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT04419649ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06656494Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Ichan School of Medicine at Mount Sinai, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT05308264Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, New York
RecruitingPhase 1/2
Ages 16 and older · All sexes · Updated Jul 20, 2026 · NCT07155226Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
- Albany Medical Center, Albany
RecruitingObservational study
Up to age 30 · All sexes · Updated Jul 16, 2026 · NCT04968834Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
- Wilmot Cancer Institute, University of Rochester, Rochester
RecruitingEarly phase 1
Ages 18 to 75 · All sexes · Updated Jun 3, 2026 · NCT03964506Cord Blood Transplantation in Children and Young Adults With Blood Cancer
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RecruitingPhase 2
Up to age 26 · All sexes · Updated May 14, 2026 · NCT07566377A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Roswell Park Comprehensive Cancer Center, Buffalo
- New York University Langone Hospital - Long Island, Mineola
- Perlmutter Cancer Center - 34th Street, New York
- and 2 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06146257A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- The University of Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT05732103Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 25, 2026 · NCT07107126A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
- Montefiore Medical Center, The Bronx
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 3, 2026 · NCT07283094CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Roswell Park Cancer Institute, Buffalo
- New York University, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT05143996Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
- Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM), The Bronx
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jan 8, 2026 · NCT05342584Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- Montefiore Medical Center, The Bronx
- White Plains Hospital, White Plains
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 5, 2026 · NCT05184842Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- Montefiore Medical Center, The Bronx
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 23, 2025 · NCT04245397Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
- Montefiore Medical Center, The Bronx
RecruitingPhase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT05986240SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Buffalo
- Massive Bio SYNERGY-AI site, Hempstead
- Massive Bio SYNERGY-AI site, Manhasset
- and 2 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Umbilical Cord Blood Transplantation From Unrelated Donors
- Wilmot Cancer Institute, Rochester
RecruitingObservational study
2 Months – 75 Years · All sexes · Updated Oct 10, 2025 · NCT03016806A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
- University of Rochester Medical Center, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 17, 2025 · NCT01311258Study of REM-422 in Patients With AML or Higher Risk MDS
- Memorial Sloan Kettering, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 23, 2025 · NCT06297941Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Memorial Sloan-Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2024 · NCT04243785From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.